JPND multinational research projects on personalised medicine for neurodegenerative diseases
The EU Joint Programme – Neurodegenerative Disease Research (JPND) has launched a new cohesive action with the European Commission – a call for “Multinational research projects on Personalised Medicine for Neurodegenerative Diseases”. More than €30 million have already been earmarked by JPND member countries and the European Commission for this action.
Neurodegenerative diseases are debilitating and still largely untreatable conditions. They are characterised by a large variability in their origins, mechanisms and clinical expression. When searching for a medical solution, for example a treatment or an optimised approach for care, this large variability constitutes a major hurdle if not controlled. Indeed a treatment addressing one disease pathway may not be useful for all patients experiencing the relevant symptoms. Thus, one of the greatest challenges for treating neurodegenerative diseases is the deciphering of this variability.
JPND has chosen to focus in the area of precision medicine, which relates to the targeting of specific elements responsible for pathology in a given individual at a particular point in time. It is an emerging approach for disease prevention, diagnosis and treatment that takes into account individual variability in genes, biological/molecular characteristics together with environmental and lifestyle factors.
The call is for multidisciplinary research proposals and will focus on precision medicine in the following research areas:
- diagnosis (for example, biomarkers, imaging data, omics approaches, big data analyses)
- prevention (for example, biomarkers for studying novel treatments and interventions, co-morbidities, digital technologies, stratification within cohort studies and clinical trials)
- care (for example, improvement of social and health care systems, molecular profiling, imaging, lifestyle data).
The following neurodegenerative diseases are included in the call:
- Alzheimer’s disease and other dementias
- Parkinson’s disease and PD‐related disorders
- prion diseases
- motor neurone diseases
- Huntington’s disease
- spinocerebellar ataxia (SCA)
- spinal muscular atrophy (SMA).
JPND is committed to patient and public involvement and proposals are expected to engage patients, carers and the public.
This will be a two-step call, with a pre-proposal submission deadline of 12 March 2019. Further details about the call are published on the JPND website.
MRC-specific queries should be directed to the following link: firstname.lastname@example.org